Tesamorelin: the FDA-approved GHRH analogue, explained

Last updated 2026-07-24

What is tesamorelin and how does it work?

Tesamorelin is a synthetic analogue of growth hormone releasing hormone (GHRH). It binds GHRH receptors on the pituitary and stimulates the body's own pulsatile release of growth hormone, which in turn raises IGF-1. It does not inject growth hormone directly; it prompts the pituitary to make more of its own, which is a meaningfully different pharmacology than exogenous HGH. The molecule was engineered for stability. Native GHRH degrades fast in circulation, so tesamorelin has a trans-3-hexenoic acid group added to the N-terminus, which slows enzymatic breakdown and extends its action long enough for once-daily subcutaneous dosing ^[1]. A 2015 population pharmacokinetic analysis in HIV-infected patients and healthy subjects confirmed this dosing pattern holds across body weight ranges and found no clinically important pharmacokinetic differences that would require routine dose adjustment by weight ^[2]. It is given as a daily subcutaneous injection, not a pill. Despite what some marketing pages imply, there is no FDA-approved oral tesamorelin peptide. Any oral version on the market is not the approved drug and has not gone through the same trials.

Is tesamorelin FDA-approved, and for what?

Yes, with a narrow label. Tesamorelin is FDA-approved under the brand name Egrifta (and later Egrifta SV) specifically to reduce excess abdominal visceral fat in adults with HIV-associated lipodystrophy. That is the entire approved indication. It is not approved for general weight loss, for reducing subcutaneous fat, for bodybuilding use, for anti-aging, or for GH replacement in people without HIV lipodystrophy. The approval rested on pooled phase 3 data. A 2010 analysis in the Journal of Clinical Endocrinology and Metabolism pooled two multicenter, double-blind, placebo-controlled phase 3 trials in HIV patients with excess abdominal fat, including safety extension data, and this pooled dataset is the backbone of the FDA approval ^[3]. You can confirm the approved label and formulations directly in the FDA's own drug database [Drugs@FDA] rather than taking a supplier's word for it. This distinction matters more than most sourcing pages let on. An FDA approval for a narrow lipodystrophy indication is real, hard-won evidence. It is not evidence that tesamorelin works for a 35-year-old lifter who just wants leaner abs. Anyone using it outside HIV-associated lipodystrophy is using it off-label, and the trial evidence for that broader use largely doesn't exist yet.

What did the phase 3 trials actually show for visceral fat?

The core registration trials measured visceral adipose tissue (VAT) by CT scan, more than waist circumference or body weight, which is a meaningfully harder endpoint to move. The pooled phase 3 analysis found significant reductions in VAT with tesamorelin versus placebo over the treatment period, along with improvements in triglycerides, in HIV patients with lipodystrophy-associated excess abdominal fat ^[3]. A related analysis looked specifically at whether patients with dorsocervical fat (the so-called buffalo hump) responded differently. This post hoc analysis of the phase III placebo-controlled trial found tesamorelin reduced VAT in both patients with and without dorsocervical fat, suggesting the visceral fat effect isn't dependent on that specific fat distribution pattern ^[4]. More recent work asked a subtler question: does tesamorelin change fat quality, more than fat quantity? A 2021 study in AIDS found tesamorelin improves fat quality (measured by adipose tissue density/attenuation on CT, a marker linked to metabolic health) independent of the actual reduction in fat amount, meaning the tissue itself may function better, more than shrink ^[5]. A 2026 meta-analysis of randomized controlled trials pooled body composition, hepatic fat, and metabolic and safety outcomes across the tesamorelin RCT literature in HIV-associated lipodystrophy, reinforcing the consistency of the VAT reduction signal across trials ^[6]. What the trials do not show: durable fat loss after stopping, effects in people without HIV lipodystrophy, or subcutaneous fat reduction as a primary benefit. The drug's specialty is visceral fat specifically.

How is tesamorelin dosed?

The approved dosing is a 2 mg subcutaneous injection once daily, reconstituted from lyophilized powder and injected into the abdomen, rotating injection sites to avoid lipodystrophy at the injection site itself. This is the dose studied in the core phase 3 program and the dose reflected in the approved label ^[3]. Dosing is not something to eyeball. Reconstitution volume, injection technique, and storage after mixing all affect how much active drug actually gets into the patient, and errors here are a common reason people think a batch "isn't working." If you want the mechanics spelled out step by step, see our tesamorelin dosage guide and the tesamorelin reconstitution walkthrough, and use the tesamorelin dosage calculator to check your math rather than trusting a forum post. The population PK data show once-daily dosing is grounded in real modeling of drug exposure over time across a range of patient weights, not an arbitrary round number ^[2]. That is worth knowing if you see off-label protocols proposing different frequencies. Those protocols are not what was tested.

What does tesamorelin do for HIV-associated lipodystrophy specifically?

HIV-associated lipodystrophy is a recognized clinical syndrome, more than "gaining weight in a bad spot." It involves abnormal fat redistribution, often central/visceral fat accumulation combined with peripheral subcutaneous fat loss, and it is linked to antiretroviral therapy history and to the metabolic effects of chronic HIV infection itself. A 2022 review in the Journal of Clinical Endocrinology and Metabolism lays out the diagnostic approach to lipodystrophy syndromes generally, distinguishing HIV-associated forms from genetic lipodystrophies ^[7], and a 2012 French paper covers the same diagnostic framework in more clinical detail ^[8]. Tesamorelin targets the visceral component of that redistribution. Beyond the VAT reduction itself, downstream studies have looked at liver and metabolic effects. A 2017 study in AIDS found that visceral fat reduction with tesamorelin was associated with improved liver enzymes in HIV patients, linking the anatomical change to a functional one ^[9]. A 2019 randomized, double-blind, multicenter trial in The Lancet HIV went further and tested tesamorelin against non-alcoholic fatty liver disease (NAFLD) in HIV patients directly, finding benefit on hepatic fat measures ^[10]. Mechanistic follow-up work has tried to explain why: a 2020 JCI Insight paper examined hepatic transcriptomic signatures after tesamorelin in HIV-associated NAFLD ^[11], and a 2021 Scientific Reports paper mapped proteomic and transcriptomic response pathways in the same condition ^[12]. There's also an inflammation angle. A 2011 AIDS study found tesamorelin's reduction in inflammatory markers in HIV patients with excess abdominal fat tracked with the degree of visceral fat reduction, suggesting the metabolic benefit and the anatomical benefit move together rather than being separate effects ^[13]. Most recently, a 2024 AIDS study examined efficacy and safety of tesamorelin specifically in people with HIV on modern integrase inhibitor regimens, which matters because antiretroviral backbone has shifted a lot since the original phase 3 trials were run, and this newer analysis extends the evidence base to today's typical HIV treatment context ^[14].

Does tesamorelin help with cognition or is that just marketing?

There is real research on this, but it is early and the population studied is narrow. A 2025 study in the Journal of Infectious Diseases examined tesamorelin's effects on neurocognitive impairment specifically in persons with HIV and abdominal obesity, testing whether GH axis stimulation has measurable cognitive effects in that population ^[15]. This is not evidence for cognitive enhancement in the general population, and it should not be read that way. It is a hypothesis-generating line of research in a specific patient group (HIV-positive people with abdominal obesity) who already have elevated risk of HIV-associated neurocognitive changes. If you see tesamorelin marketed broadly as a nootropic or brain-health peptide, that claim is running well ahead of the data currently available.

Is tesamorelin used off-label for bodybuilding or general fat loss?

Yes, this happens, and it is worth being blunt about it: the trial evidence does not cover this use. Tesamorelin bodybuilding use and general "visceral fat reduction for aesthetics" use in people without HIV-associated lipodystrophy relies on extrapolating from the HIV lipodystrophy trials, plus general knowledge of the GH/IGF-1 axis, not on dedicated trials in healthy or non-HIV populations. A 2013 review in Best Practice & Research Clinical Endocrinology & Metabolism covers growth hormone physiology in the aging male broadly, including how GH secretion changes with age, but it is not a tesamorelin efficacy trial and shouldn't be cited as one ^[16]. Two 2026 sports-medicine-adjacent papers are useful context here: one on injectable peptide therapy as a primer for orthopaedic and sports medicine physicians surveys the broader peptide-in-sports landscape ^[17], and a companion piece on therapeutic peptides in orthopaedics covers applications, challenges, and open questions across the class, tesamorelin included as one example among many peptides being explored ^[18]. A 2026 Sports Medicine review on safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance is explicit that much of this space runs ahead of controlled trial evidence ^[19]. The honest read: if you're using tesamorelin for physique reasons rather than diagnosed HIV lipodystrophy, you're using an approved drug in a way its trials never tested. That doesn't automatically make it dangerous, but it does mean nobody can hand you a number for "expected fat loss" the way the phase 3 VAT data can for the approved indication. Anecdote is not the same as a CT-measured endpoint.

What are the real risks and side effects?

The most consistent side effects reported across the tesamorelin literature are injection site reactions (redness, itching, sometimes small nodules), joint pain (arthralgia), and swelling from fluid retention, all of which are mechanistically expected from raising GH/IGF-1. Because tesamorelin raises IGF-1, it carries a caution around active malignancy; it is not recommended in patients with an active cancer, since GH axis stimulation could theoretically support tumor growth, and this caution appears across the pharmacology reviews of the drug ^[20][21]. Glucose tolerance is another area to watch. GH-axis stimulation can raise blood glucose and reduce insulin sensitivity somewhat, which is relevant for people with pre-diabetes or diabetes, and this is a recognized class effect worth discussing with a prescriber before starting, not something to self-manage. A 2011 review of tesamorelin's use in HIV-associated lipodystrophy management covers this safety profile against its efficacy ^[21], and a 2012 pharmacotherapy-focused review in Annals of Pharmacotherapy walks through the same tradeoffs from a prescribing standpoint ^[22]. For a full breakdown of what to expect and what to flag to a provider, see tesamorelin peptide side effects. If you want the plainest possible summary: this is a drug that meaningfully activates an endocrine axis, and it should be used under medical supervision with basic labs (IGF-1, glucose, possibly liver enzymes given the NAFLD data) rather than self-directed with no monitoring.

How is tesamorelin different from HGH, sermorelin, or ipamorelin?

This confuses a lot of people because all of these get lumped into "GH peptides" in marketing copy, but the mechanisms differ. | Compound | Class | FDA status | Mechanism |

How much does tesamorelin cost, and is it covered by insurance?

Cost varies a lot depending on whether you're getting the branded, FDA-approved Egrifta/Egrifta SV product through a prescription with insurance coverage for the labeled HIV lipodystrophy indication, versus paying out of pocket for off-label use, where insurance typically will not cover it at all since the diagnosis doesn't match the label. This is genuinely one of the biggest practical barriers to the approved use case: even patients who clearly qualify under the HIV lipodystrophy label can face high out-of-pocket costs if insurance prior authorization is denied or delayed. For a detailed cost breakdown across brand and off-label sourcing routes, see tesamorelin cost. We'd rather be honest here than sell you something: if you don't have HIV-associated lipodystrophy, you are not going to get insurance to pay for tesamorelin, and you should budget accordingly before starting.

What results can you actually expect, and over what timeframe?

In the approved indication, the phase 3 program measured VAT reduction over roughly 26 weeks of active treatment, with safety extension data carrying that observation further, and the pooled analysis is the clearest single source for magnitude and timing of effect ^[3]. Fat quality changes (density on CT) were also detectable in that same general timeframe in the 2021 AIDS analysis ^[5]. Two things worth being honest about. First, effects are not necessarily durable after stopping treatment; the trials that show benefit are trials of continued dosing, not one-time or short-course use. Second, "visceral fat reduction" as an endpoint does not mean visible six-pack abs or dramatic scale weight change; VAT is fat around the organs, measured by CT, and its reduction correlates with metabolic markers (liver enzymes, some inflammatory markers) more reliably than with cosmetic appearance ^[9][13]. If you want to see what before/after actually looks like in terms of documented outcomes rather than testimonials, tesamorelin peptide before and after breaks down the trial-reported changes in more visual terms. Detection matters too, for anyone wondering whether tesamorelin use shows up on testing: a 2021 paper in Drug Testing and Analysis reviews advances in detecting GHRH synthetic analogues, relevant mostly to anti-doping contexts rather than clinical care ^[27].

Where does tesamorelin fit if you're considering it through Tesamorelin Co?

If you've read this far and you actually have a diagnosis of HIV-associated lipodystrophy with excess visceral fat, tesamorelin has the strongest trial evidence of any peptide in this general category, full stop. That's a real FDA approval built on CT-verified phase 3 outcomes, not a supplement claim. If you're considering it off-label, go in clear-eyed: you're relying on mechanism and on trial data from a different population, not on a trial in people like you. Tesamorelin Co does not compound or manufacture tesamorelin itself; the practical path is a provider-reviewed evaluation that routes any prescription through a licensed, fulfilling pharmacy partner, so dosing, sourcing, and monitoring aren't left to guesswork. Either way, don't self-diagnose the visceral fat problem and don't self-manage the monitoring. Get actual labs, get an actual diagnosis if you're pursuing the approved pathway, and treat off-label use as the open question it genuinely still is.

Frequently asked questions

What is tesamorelin used for?

Tesamorelin is FDA-approved (as Egrifta/Egrifta SV) to reduce excess visceral abdominal fat in adults with HIV-associated lipodystrophy. Phase 3 trials measured this with CT scans and found significant reductions versus placebo. Any other use, including general fat loss, bodybuilding, or anti-aging, is off-label and lacks the same dedicated trial evidence.

Is tesamorelin the same as HGH?

No. Tesamorelin is a GHRH analogue that stimulates your own pituitary gland to release more growth hormone. HGH (somatropin) is exogenous growth hormone injected directly, bypassing pituitary stimulation entirely. The mechanisms and regulatory pathways for the two are different, though both raise IGF-1.

What is the standard tesamorelin dosing schedule?

The approved dose studied in phase 3 trials is 2 mg once daily by subcutaneous injection into the abdomen, with rotated injection sites. See the tesamorelin dosage guide for reconstitution details and a dosage calculator to double-check your prep before injecting.

Can tesamorelin be taken orally?

No approved oral tesamorelin exists. The FDA-approved product is a subcutaneous injection. Any product marketed as an oral tesamorelin peptide is not the studied, approved drug, and its bioavailability and effects have not been established in the phase 3 trial program.

Does tesamorelin help with weight loss generally, more than visceral fat?

The trial evidence is specific to visceral adipose tissue reduction in HIV-associated lipodystrophy, not general body weight loss. Pooled phase 3 data showed VAT reductions and improved triglycerides, but tesamorelin is not studied or approved as a general weight-loss drug.

Is tesamorelin safe, and what are the main side effects?

Common side effects include injection site reactions, joint pain, and fluid retention/swelling, consistent with raising the GH/IGF-1 axis. It is not recommended for people with active malignancy, and glucose tolerance should be monitored since GH stimulation can affect insulin sensitivity. Use it under medical supervision with baseline labs.

Does tesamorelin affect the liver?

Yes, there is real trial data here. A 2019 randomized, double-blind trial in The Lancet HIV found tesamorelin improved hepatic fat measures in HIV-associated NAFLD, and a 2017 AIDS study linked visceral fat reduction with improved liver enzymes. This is specific to the HIV lipodystrophy population studied.

Is tesamorelin used in bodybuilding, and does it work for that?

It is used off-label in bodybuilding and general fitness contexts, largely extrapolating from GH-axis physiology and the HIV lipodystrophy trials rather than from dedicated trials in healthy or athletic populations. No controlled trial has established expected outcomes for this use, so treat bodybuilding claims as unproven rather than evidence-based.

How is tesamorelin different from sermorelin or ipamorelin?

Tesamorelin and sermorelin are both GHRH analogues that stimulate pituitary GH release, while ipamorelin works through the ghrelin receptor, a different pathway. Tesamorelin is the only one with an FDA-approved indication backed by phase 3, CT-verified visceral fat outcome data; the others are typically sourced as compounded or research peptides.

Does insurance cover tesamorelin?

Insurance coverage is realistic mainly for the approved indication, HIV-associated lipodystrophy with documented excess visceral fat, and even then prior authorization can be a hurdle. Off-label use is almost never covered, meaning it is paid out of pocket. See the tesamorelin cost page for a fuller breakdown.

Does tesamorelin help with cognitive function?

A 2025 study in the Journal of Infectious Diseases examined tesamorelin's effects on neurocognitive impairment specifically in people with HIV and abdominal obesity. This is early, population-specific research, not evidence for general cognitive enhancement, and it should not be extrapolated beyond that studied group.

How long does it take to see results from tesamorelin?

Phase 3 trials measured visceral fat and fat-quality changes over roughly 26 weeks of continued daily dosing, with safety extension data following patients longer. Effects are tied to ongoing treatment rather than a one-time course, and there isn't strong evidence that benefits persist after stopping.

Sources

1. Nature Reviews Drug Discovery, Tesamorelin (2011): Tesamorelin is a GHRH analogue engineered with an N-terminal modification for extended stability enabling once-daily dosing
2. Clinical Pharmacokinetics, Population pharmacokinetic analysis of tesamorelin (2015): Population PK analysis in HIV-infected patients and healthy subjects supports once-daily dosing without major weight-based adjustment
3. Journal of Clinical Endocrinology and Metabolism, pooled phase 3 tesamorelin trials (2010): Pooled analysis of two phase 3 double-blind placebo-controlled trials found significant visceral adipose tissue reduction and improved triglycerides with tesamorelin
4. Journal of Clinical and Translational Science, post hoc dorsocervical fat analysis (2023): Post hoc phase 3 analysis found tesamorelin reduced visceral fat in patients both with and without dorsocervical fat
5. AIDS, Tesamorelin improves fat quality independent of fat quantity (2021): Tesamorelin improved fat quality (CT attenuation/density) independent of changes in fat quantity
6. Obesity Research & Clinical Practice, tesamorelin meta-analysis of RCTs (2026): Meta-analysis of RCTs pooled body composition, hepatic fat, metabolic and safety outcomes of tesamorelin in HIV-associated lipodystrophy
7. Journal of Clinical Endocrinology and Metabolism, Approach to the Patient With Lipodystrophy (2022): Clinical framework for diagnosing lipodystrophy syndromes, distinguishing HIV-associated from genetic forms
8. Annales d'Endocrinologie, How to diagnose a lipodystrophy syndrome (2012): Diagnostic criteria and clinical approach to lipodystrophy syndromes
9. AIDS, visceral fat reduction and liver enzymes (2017): Visceral fat reduction with tesamorelin was associated with improved liver enzymes in HIV patients
10. The Lancet HIV, tesamorelin and NAFLD randomized trial (2019): Randomized double-blind multicenter trial found tesamorelin improved hepatic fat measures in HIV-associated NAFLD
11. JCI Insight, hepatic transcriptomic signatures (2020): Study examined hepatic transcriptomic signatures following tesamorelin treatment in HIV-associated NAFLD
12. Scientific Reports, tesamorelin response pathways in NAFLD (2021): Targeted proteomic and transcriptomic analysis mapped tesamorelin response pathways in HIV-associated NAFLD
13. AIDS, inflammatory markers and visceral fat reduction (2011): Reduction in inflammatory markers with tesamorelin tracked with degree of visceral adipose reduction
14. AIDS, tesamorelin in people with HIV on integrase inhibitors (2024): Efficacy and safety of tesamorelin was assessed in people with HIV on modern integrase inhibitor regimens
15. Journal of Infectious Diseases, tesamorelin and neurocognitive impairment (2025): Study examined tesamorelin effects on neurocognitive impairment in persons with HIV and abdominal obesity
16. Best Practice & Research Clinical Endocrinology & Metabolism, growth hormone in the aging male (2013): Review covers growth hormone physiology and secretion changes in aging men, general GH axis context
17. American Journal of Sports Medicine, Injectable Peptide Therapy primer (2026): Primer for sports medicine physicians surveys injectable peptide therapies including GH-axis peptides used off-label
18. JAAOS Global Research & Reviews, Therapeutic Peptides in Orthopaedics (2026): Review covers applications and open challenges of therapeutic peptides including GH-axis peptides in orthopaedic contexts
19. Sports Medicine, Safety and Efficacy of Peptide Therapies for Musculoskeletal Injuries (2026): Review states evidence for many approved and unapproved peptide therapies in athletic performance contexts lags behind use
20. Expert Opinion on Investigational Drugs, Tesamorelin (2009): Pharmacology review covers tesamorelin safety considerations including malignancy caution tied to IGF-1 elevation
21. Drugs, Tesamorelin review in HIV-associated lipodystrophy (2011): Review of tesamorelin's efficacy and safety profile in management of HIV-associated lipodystrophy
22. Annals of Pharmacotherapy, Tesamorelin GHRF analogue review (2012): Pharmacotherapy-focused review discusses prescribing tradeoffs and safety monitoring for tesamorelin
23. eCFR, 21 CFR 216.23 final 503A Bulks List: Federal regulation establishing the bulk drug substances list for 503A pharmacy compounding
24. eCFR, 21 CFR 216.24 the 503B Bulks List: Federal regulation establishing the bulk drug substances list for 503B outsourcing facility compounding
25. Cornell Law/Legal Information Institute, 21 U.S.C. 353a pharmacy compounding: Statute governing conditions under which pharmacy compounding is exempt from certain FDA drug approval requirements
26. FDA, bulk drug substances nominated for use in compounding under section 503A: FDA's current list of bulk drug substances nominated for compounding, which determines legal compounding status of GHRH-class peptides
27. Drug Testing and Analysis, detection of GHRH synthetic analogs (2021): Review covers advances in analytical detection methods for GHRH synthetic analogues including tesamorelin